Importantly, using anti-BCMA BiTEs as a partner in combination therapy, including with CAR T cells, immunomodulatory drugs, and vaccines, has the potential to further improve outcomes for patients with MM. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.